Chuanming Lin, Shuiling Xie, Menger Wang, Bin Yang, Jianzhen Shen
{"title":"Angiogenesis-related gene signature for prognostic prediction and immune microenvironment characterization in diffuse large B-cell lymphoma.","authors":"Chuanming Lin, Shuiling Xie, Menger Wang, Bin Yang, Jianzhen Shen","doi":"10.1007/s10238-025-01628-9","DOIUrl":null,"url":null,"abstract":"<p><p>Diseases often result from multiple factors, and angiogenesis-related genes (ARGs) have been demonstrated to be associated with cancer. However, their role in diffuse large B-cell lymphoma (DLBCL) has not been fully elucidated. ARGs associated with DLBCL prognosis were identified utilizing Cox regression and LASSO analyses. A prognostic model was constructed based on 7 ARGs, and its biological function was analyzed. Differences in the tumor immune microenvironment based on the prognostic signature were evaluated. Finally, DLBCL cell experiments confirmed the differential expression of genes in DLBCL. The prognostic value of ARGs in DLBCL patients was comprehensively analyzed for the first time, identifying 7 ARGs with prognostic significance. A prognostic risk model was constructed based on these 7 ARGs and validated on an independent external DLBCL dataset. In DLBCL patients, this prognostic feature was an independent risk factor and significantly correlated with clinical characteristics. This feature was also associated with the immune microenvironment of DLBCL. DLBCL cell experiments confirmed significant expression of the 7 ARGs in DLBCL cells. This research provides a fundamental theoretical basis for improving the diagnosis and treatment of DLBCL in clinical practice.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"108"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01628-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Diseases often result from multiple factors, and angiogenesis-related genes (ARGs) have been demonstrated to be associated with cancer. However, their role in diffuse large B-cell lymphoma (DLBCL) has not been fully elucidated. ARGs associated with DLBCL prognosis were identified utilizing Cox regression and LASSO analyses. A prognostic model was constructed based on 7 ARGs, and its biological function was analyzed. Differences in the tumor immune microenvironment based on the prognostic signature were evaluated. Finally, DLBCL cell experiments confirmed the differential expression of genes in DLBCL. The prognostic value of ARGs in DLBCL patients was comprehensively analyzed for the first time, identifying 7 ARGs with prognostic significance. A prognostic risk model was constructed based on these 7 ARGs and validated on an independent external DLBCL dataset. In DLBCL patients, this prognostic feature was an independent risk factor and significantly correlated with clinical characteristics. This feature was also associated with the immune microenvironment of DLBCL. DLBCL cell experiments confirmed significant expression of the 7 ARGs in DLBCL cells. This research provides a fundamental theoretical basis for improving the diagnosis and treatment of DLBCL in clinical practice.
期刊介绍:
Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.